WGS GeneDx Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: WGS

Price (delayed)

$19.66

Market cap

$513.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.18

Enterprise value

$548.64M

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic ...

Highlights
GeneDx Holdings's EPS has surged by 89% YoY and by 28% QoQ
The net income has soared by 75% YoY and by 23% QoQ
WGS's debt has surged by 57% year-on-year
The company's equity fell by 37% YoY and by 9% QoQ
Sector: Healthcare
Industry: Health Information Services
Website: http://sema4.com
Peers: NEOG NTRA MYGN

Key stats

What are the main financial stats of WGS
Market
Shares outstanding
26.14M
Market cap
$513.95M
Enterprise value
$548.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.47
Price to sales (P/S)
2.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.47
Earnings
Revenue
$221.85M
EBIT
-$134.73M
EBITDA
-$104.53M
Free cash flow
-$142.66M
Per share
EPS
-$5.18
Free cash flow per share
-$5.47
Book value per share
$7.95
Revenue per share
$8.51
TBVPS
$8.65
Balance sheet
Total assets
$394.53M
Total liabilities
$187.31M
Debt
$118.37M
Equity
$207.22M
Working capital
$112.69M
Liquidity
Debt to equity
0.57
Current ratio
3.22
Quick ratio
2.8
Net debt/EBITDA
-0.33
Margins
EBITDA margin
-47.1%
Gross margin
50.6%
Net margin
-60.9%
Operating margin
-60.5%
Efficiency
Return on assets
-31.6%
Return on equity
-54.8%
Return on invested capital
-76.3%
Return on capital employed
-39.2%
Return on sales
-60.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

WGS stock price

How has the GeneDx Holdings stock price performed over time
Intraday
0.82%
1 week
77.44%
1 month
108.04%
1 year
-92.66%
YTD
614.91%
QTD
115.33%

Financial performance

How have GeneDx Holdings's revenue and profit performed over time
Revenue
$221.85M
Gross profit
$112.18M
Operating income
-$134.23M
Net income
-$135.02M
Gross margin
50.6%
Net margin
-60.9%
The operating income has soared by 79% YoY and by 26% from the previous quarter
The operating margin has soared by 79% YoY and by 32% from the previous quarter
The net income has soared by 75% YoY and by 23% QoQ
WGS's net margin has surged by 74% year-on-year and by 30% since the previous quarter

Growth

What is GeneDx Holdings's growth rate over time

Valuation

What is GeneDx Holdings stock price valuation
P/E
N/A
P/B
2.47
P/S
2.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.47
GeneDx Holdings's EPS has surged by 89% YoY and by 28% QoQ
The company's equity fell by 37% YoY and by 9% QoQ
WGS's revenue is up by 10% since the previous quarter

Efficiency

How efficient is GeneDx Holdings business performance
The ROIC has soared by 83% YoY and by 36% from the previous quarter
GeneDx Holdings's return on sales has surged by 77% YoY and by 31% QoQ
The ROA has soared by 59% year-on-year and by 16% since the previous quarter
The ROE has soared by 54% YoY and by 14% from the previous quarter

Dividends

What is WGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for WGS.

Financial health

How did GeneDx Holdings financials performed over time
WGS's total assets is 111% greater than its total liabilities
The current ratio has increased by 41% year-on-year and by 3.9% since the previous quarter
WGS's quick ratio is up by 35% year-on-year
WGS's debt is 43% smaller than its equity
The debt to equity has surged by 148% year-on-year and by 10% since the previous quarter
WGS's debt has surged by 57% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.